Seventh Sense Biosystems Announces Expansion of Manufacturing Operations and Facilities in Medford, Massachusetts

Seventh Sense Biosystems Announces Expansion of Manufacturing Operations and Facilities in Medford, Massachusetts

September 21, 2015

MEDFORD, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems, Inc., (7SBio), a leading developer of blood collection and diagnostic platforms, announced today it is expanding its manufacturing operations and relocating its home office.

Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer

Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer

September 21, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, the industry pioneer in gene control, announced today that accomplished industry veteran Kyle Kuvalanka joined the Company as its first Chief Operating Officer. In this newly created role, Mr. Kuvalanka will hold broad management responsibility for finance, business development, new product planning, and other business operations, as well as the Company’s proprietary gene control mapping platform.

Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism

Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism

September 9, 2015

Acquisition Complements Agilent's Market-Leading Separations and Mass Spectrometry Solutions, Expands Pharma Offerings

SANTA CLARA, Calif., and BILLERICA, Mass., Sept. 9, 2015 Agilent Technologies Inc. (NYSE: A) and Seahorse Bioscience today announced they have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.

Dow, Honeywell and Novomer finalists for PU innovation award

Dow, Honeywell and Novomer finalists for PU innovation award

September 9, 2015

The Center for the Polyurethanes Industry has announced the finalists for the 2015 Polyurethane Innovation Award: Dow Chemical Co., Honeywell International Inc. and Novomer Inc.

The winner will be announced on Oct. 7, the final day of the 2015 Polyurethanes Technical Conference in Orlando, Fla. The three commercial technologies will be presented during the opening session on Oct. 5. Attendees at the opening session will vote, and that tally will be combined with scores from professional judges to determine the winner.

The three finalist innovations are:  

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

September 9, 2015

CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, and Serum Institute of India Ltd. (Serum Institute), a global leader in vaccine development and manufacturing, today announced that the companies have entered into a license agreement for the development, manufacture and commercialization of VIS513 in the Indian subcontinent countries.

Flagship Ventures Adds Internal IP Counsel

Flagship Ventures Adds Internal IP Counsel

September 9, 2015

Biotech industry veteran Leda Trivinos to lead expansion of firm’s internal innovation and patenting program

Cambridge, Mass., Sept. 9, 2015/PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has hired Leda Trivinos, Ph.D., as Partner, Intellectual Property. Trivinos will play a key role as Flagship scales the company creation activities of its VentureLabs innovation foundry.

Denali Therapeutics Appoints Steve E. Krognes as Chief Financial Officer

Denali Therapeutics Appoints Steve E. Krognes as Chief Financial Officer

September 8, 2015

SOUTH SAN FRANCISCO, September 8, 2015 – Denali Therapeutics Inc. (“Denali”), a biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that Steve E. Krognes will join the company as Chief Financial Officer effective October 1, 2015. As a member of the Executive Leadership Team, Mr. Krognes will lead the finance function and certain other administrative functions.

Selecta Announces $38 Million Series E Financing

Selecta Announces $38 Million Series E Financing

September 8, 2015

Proceeds from financing to enable advancement of multiple product pipeline of antigen-specific immunotherapies and vaccines

Phase 2 study of lead immunotherapeutic candidate, SEL-212, in gout planned to start in 2016

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

August 21, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics platform company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SER-109, an oral therapeutic currently in a Phase 2 clinical trial for the prevention of recurrent Clostridium Difficile infection (CDI) in adults. SER-109 is being investigated as a new therapeutic modality to treat recurrent CDI by correcting a dysbiosis of the human microbiome, which is an underlying cause of the condition.

Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains

Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains

August 18, 2015

– Preclinical Studies Published in the Proceedings of the National Academy of Sciences –